Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
ZVRA similar filings
- 9 Nov 16 KemPharm, Inc. Reports Third Quarter 2016 Results
- 18 Oct 16 KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
- 3 Oct 16 Entry into a Material Definitive Agreement
- 21 Sep 16 Other Events
- 15 Sep 16 KemPharm, Inc. Provides Corporate and Clinical Update
- 11 Aug 16 Other Events
- 10 Aug 16 KemPharm, Inc. Reports Second Quarter 2016 Results
Filing view
External links
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide2.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide3.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide4.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide5.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide6.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide7.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide8.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide9.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide10.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide11.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide12.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide13.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide14.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide15.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide16.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide17.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide18.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide19.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide20.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide21.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide22.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide23.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide24.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide25.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide26.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide27.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide28.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide29.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide30.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide31.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide32.jpg)
![](https://capedge.com/proxy/8-K/0001437749-16-038951/slide33.jpg)